| 2026-03-18 |
股东大会：
将于2026-05-01召开股东大会
会议内容 ▼▲
- 1.To elect nine directors to the Board of Directors (page 14)
2.To approve, by non-binding advisory vote, the compensation paid to named executive officers (page 50)
3.To ratify the appointment of KPMG LLP to be our independent registered public accounting firm for the fiscal year ending December 31, 2026 (page 90)
4.To approve Amendment No. 1 to the AMN Healthcare 2025 Equity Plan (page 93)
5.Shareholder Proposal (page 101)
|
| 2026-03-18 |
详情>>
股本变动：
变动后总股本3865.62万股
|
| 2026-02-20 |
详情>>
业绩披露：
2025年年报每股收益-2.48美元,归母净利润-9570.2万美元,同比去年增长34.89%
|
| 2026-02-19 |
财报披露：
美东时间 2026-02-19 盘后发布财报
|
| 2026-01-15 |
详情>>
内部人交易：
Scott Brian M.等共交易19笔
|
| 2025-11-07 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-2.29美元,归母净利润-8800.6万美元,同比去年增长-317.01%
|
| 2025-08-08 |
详情>>
业绩披露：
2025年中报每股收益-3.06美元,归母净利润-1.17亿美元,同比去年增长-449.45%
|
| 2025-05-09 |
详情>>
业绩披露：
2025年一季报每股收益-0.03美元,归母净利润-109.2万美元,同比去年增长-106.3%
|
| 2025-03-18 |
股东大会：
将于2025-05-02召开股东大会
会议内容 ▼▲
- 1.To elect nine directors to the Board of Directors
2.To approve, by non-binding advisory vote, the compensation paid to named executive officers
3.To ratify the appointment of KPMG LLP to be our independent registered public accounting firm for the fiscal year ending December 31, 2025
4.To approve the AMN Healthcare 2025 Equity Plan
5.Shareholder Proposal
|
| 2025-02-21 |
详情>>
业绩披露：
2024年年报每股收益-3.85美元,归母净利润-1.47亿美元,同比去年增长-169.76%
|
| 2025-02-21 |
详情>>
业绩披露：
2022年年报每股收益9.96美元,归母净利润4.44亿美元,同比去年增长35.63%
|
| 2024-11-08 |
详情>>
业绩披露：
2023年三季报(累计)每股收益5.01美元,归母净利润1.98亿美元,同比去年增长-45.29%
|
| 2024-11-08 |
详情>>
业绩披露：
2024年三季报(累计)每股收益1.06美元,归母净利润4055.40万美元,同比去年增长-79.54%
|
| 2024-08-09 |
详情>>
业绩披露：
2024年中报每股收益0.88美元,归母净利润3356.50万美元,同比去年增长-76.85%
|
| 2024-05-10 |
详情>>
业绩披露：
2024年一季报每股收益0.45美元,归母净利润1732.80万美元,同比去年增长-79.4%
|
| 2024-03-05 |
股东大会：
将于2024-04-19召开股东大会
会议内容 ▼▲
- 1.To elect eight directors to the Board of Directors
2.To approve, by non-binding advisory vote, the compensation paid to named executive officers
3.To ratify the appointment of KPMG LLP to be our independent registered public accounting firm for the fiscal year ending December 31, 2024
4.To approve a proposed amendment and restatement of our certificate of incorporation to provide for exculpation of certain officers of the Company from personal liability under certain circumstances as permitted by Delaware law
|
| 2024-02-22 |
详情>>
业绩披露：
2023年年报每股收益5.38美元,归母净利润2.11亿美元,同比去年增长-52.56%
|
| 2023-04-04 |
股东大会：
将于2023-05-17召开股东大会
会议内容 ▼▲
- 1.To elect nine directors to the Board of Directors
2.To approve, by non-binding advisory vote, the compensation of our named executive officers
3.To ratify the appointment of KPMG LLP to be our independent registered public accounting firm for the fiscal year ending December 31, 2023
4.To consider a shareholder proposal if properly presented at the 2023 Annual Meeting
|
| 2022-03-24 |
股东大会：
将于2022-05-06召开股东大会
会议内容 ▼▲
- 1.To elect nine directors to the Board of Directors
2.To approve, by non-binding advisory vote, the compensation of our named executive officers
3.To approve the AMN Healthcare Employee Stock Purchase Plan
4.To ratify the appointment of KPMG LLP to be our independent registered public accounting firm for the fiscal year ending December 31, 2022
5.To consider a shareholder proposal if properly presented at the 2022 Annual Meeting
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-10 |
股东大会：
将于2021-04-21召开股东大会
会议内容 ▼▲
- 1.To elect eight directors to the Board of Directors
2.To approve, by non-binding advisory vote, the compensation of our named executive officers
3.To consider the frequency of the advisory vote on the compensation of our named executive officers
4.To ratify the appointment of KPMG LLP to be our independent registered public accounting firm for the fiscal year ending December 31, 2021
5.To consider a shareholder proposal if properly presented at the 2021 Annual Meeting
|
| 2020-03-11 |
股东大会：
将于2020-04-22召开股东大会
会议内容 ▼▲
- 1.Elect eight directors nominated by our Board of Directors to hold office until our next annual meeting or until their successors are duly elected and qualified,
2.Approve, by non-binding advisory vote, the compensation of our named executive officers,
3.Ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020,
4.Approve a proposal to reduce the threshold necessary to call a special shareholders meeting;
5.Transact such other business, including consideration of a shareholder proposal if properly presented, as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2019-03-07 |
股东大会：
将于2019-04-17召开股东大会
会议内容 ▼▲
- 1.elect eight directors nominated by our Board of Directors to hold office until our next annual meeting or until their successors are duly elected and qualified,
2.approve, by non-binding advisory vote, the compensation of our named executive officers,
3.ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019,
4.transact such other business, including consideration of a shareholder proposal if properly presented, as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2018-03-08 |
股东大会：
将于2018-04-18召开股东大会
会议内容 ▼▲
- 1.elect eight directors nominated by our Board of Directors to hold office until our next annual meeting or until their successors are duly elected and qualified
2.approve, by non-binding advisory vote, the compensation of our named executive officers
3.ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018
4.transact such other business, including consideration of a shareholder proposal if properly presented, as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2017-03-09 |
股东大会：
将于2017-04-19召开股东大会
会议内容 ▼▲
- (1)elect eight directors nominated by our Board of Directors to hold office until our next annual meeting or until their successors are duly elected and qualified,
(2)approve, by non-binding advisory vote, the compensation of our named executive officers,
(3)recommend, by non-binding advisory vote, the frequency of executive compensation votes,
(4)approve the AMN Healthcare 2017 Senior Executive Incentive Bonus Plan,
(5)approve the AMN Healthcare 2017 Equity Plan,
(6)ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017,
(7)transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2017-02-17 |
复牌提示：
2017-02-16 14:59:17 停牌，复牌日期 2017-02-16 15:23:24
|